Clinical implementation and initial experience with a 1.5 Tesla MR-linac for MR-guided radiotherapy for gynecologic cancer: An R-IDEAL stage 1/2a first in humans/feasibility study of new technology implementation

David S. Lakomy, Jinzhong Yang, Sastry Vedam, Jihong Wang, Belinda Lee, Angela Sobremonte, Pamela Castillo, Neil Hughes, Mustefa Mohammadsaid, Anuja Jhingran, Ann H. Klopp, Seungtaek Choi, Clifton D. Fuller, Lilie L. LinmedRxiv 2021 · DOI

Introduction

Traditional radiotherapy for gynecologic malignancies relies on static "snapshot" CT scans for treatment planning. However, the pelvic anatomy is dynamic; organs at risk (OARs) such as the bladder, bowel, and rectum shift and deform daily. To account for this movement, clinicians typically use generous safety margins, which inadvertently increase the radiation dose to healthy tissues. The advent of magnetic resonance imaging-guided linear accelerator (MR-linac) systems offers a solution by enabling real-time visualization and daily plan adaptation. This study reports the first-in-human clinical implementation of a 1.5 Tesla MR-linac for gynecologic cancers, following the R-IDEAL framework for evaluating new medical technologies.

Methodology and Workflow

The study utilized the Elekta Unity system, which integrates a 7-MV flattening-filter-free (FFF) linear accelerator with a 1.5 Tesla MR scanner. Ten patients with various gynecologic malignancies—including cervical, endometrial, vaginal, ovarian, and peritoneal cancers—were treated over a total of 90 fractions.

Two primary daily adaptation strategies were evaluated:

  1. Adapt-to-Position (ATP): A rigid shift of the original plan to align with the tumor's daily coordinates.
  2. Adapt-to-Shape (ATS): A more intensive process involving manual re-contouring of the tumor and OARs on the daily MR image, followed by full plan re-optimization.

The researchers assessed feasibility through treatment duration, setup variability (isocenter shifts), and quality assurance (QA) pass rates. Additionally, deformable image registration was used to calculate the "accumulated dose"—the actual dose delivered across the treatment course compared to the initial reference plan.

Key Findings

Clinical Feasibility and Efficiency

The implementation proved highly reliable, with 90 of 92 planned fractions successfully delivered on the MR-linac. The median treatment duration was 32 minutes per fraction. While this is longer than conventional 15-minute IMRT slots, it remains within a clinically acceptable range for adaptive therapy. Notably, the ATP workflow was significantly faster than the ATS workflow (30 minutes vs. 42 minutes, p < 0.0001).

Precision and Quality Assurance

Despite the absence of traditional external laser alignment, the system demonstrated high geometric accuracy. The average isocenter shift was less than 0.5 cm in all axes, relying entirely on internal MR imaging for setup. Furthermore, 100% of the adapted plans passed IMRT QA testing, with a median gamma pass rate of 99.9% (using a 3%/3mm criterion).

Dosimetric Impact of Anatomical Variation

The study highlighted that the necessity of complex adaptation (ATS) depends largely on tumor location:

  • Peripheral Lesions: Tumors located in the pelvic periphery or near fixed structures (e.g., the ischium) showed stable dosimetry, with accumulated doses within 1% of the reference plan.
  • Central Lesions: Tumors such as vaginal cuff boosts were highly sensitive to daily fluctuations in bladder and rectal filling. For these cases, dose differences ranged from -5.8% to -9.6%, emphasizing the value of daily visualization and potential shape-based adaptation to maintain target coverage.

Discussion and Limitations

This R-IDEAL stage 1/2a study confirms that 1.5T MR-guided adaptive radiotherapy is feasible and provides high dosimetric stability for gynecologic patients. The ability to "see" the anatomy daily allows for confidence in target coverage even amidst significant organ motion.

However, the study's small sample size (n=10) and the heterogeneity of the patient cohort limit the ability to define specific protocols for margin reduction. Additionally, the 22-cm longitudinal field size limit of the Elekta Unity currently restricts its use for patients requiring extended-field radiation, such as those needing coverage of the para-aortic lymph nodes.

Conclusion

The MR-linac is a reliable tool for the treatment of gynecologic cancers, offering a path toward more personalized and precise radiotherapy. Future research will focus on "margin attenuation"—reducing safety margins to minimize toxicity—and exploring the use of MR-linacs as an alternative to brachytherapy for patients where the latter procedure is not an option.

Summary updated

Abstract

ABSTRACT Purpose Magnetic resonance imaging–guided linear accelerator systems (MR-linacs) can facilitate the daily adaptation of radiotherapy plans. Here, we report our early clinical experience using an MR-linac for adaptive radiotherapy of gynecologic malignancies. Methods and Materials Treatments were planned with an Elekta Monaco v5.4.01 and delivered by a 1.5 Tesla Elekta Unity MR-linac. The system offers a choice of daily adaptation based on either position (ATP) or shape (ATS) of the tumor and surrounding normal structures. The ATS approach has the option of manually editing the contours of tumors and surrounding normal structures before the plan is adapted. Here we documented the duration of each treatment fraction; set-up variability (assessed by isocenter shifts in each plan) between fractions; and, for quality assurance, calculated the percentage of plans meeting the y-criterion of 3%/3-mm distance to agreement. Deformable accumulated dose calculations were used to compare ATP plans with reference dose plans. Results Of the 10 patients treated with 90 fractions on the MR-linac, most received boost doses to recurrence in nodes or isolated tumors. Each treatment fraction lasted a median 32 minutes; fractions were shorter with ATP than with ATS (30 min vs 42 min, P &lt;0.0001). The y criterion for all fraction plans exceeded &gt;90% (median 99.9%, range 92.4%–100%), i.e., all plans passed quality assurance testing. The average extent of isocenter shift was &lt;0.5 cm in each axis. The accumulated dose to the gross tumor volume was within 10% of the reference plan for all ATP cases. Accumulated doses for lesions in the pelvic periphery were within 1% of the reference plan as opposed to –5.8% to –9.6% for central tumors. Conclusions The MR-linac is a reliable and clinically feasible tool for treating patients with gynecologic cancer.
BibTeX
@misc{lakomy2021clinical,
  author = {David S. Lakomy and Jinzhong Yang and Sastry Vedam and Jihong Wang and Belinda Lee and Angela Sobremonte and Pamela Castillo and Neil Hughes and Mustefa Mohammadsaid and Anuja Jhingran and Ann H. Klopp and Seungtaek Choi and Clifton D. Fuller and Lilie L. Lin},
  title = {{Clinical implementation and initial experience with a 1.5 Tesla MR-linac for MR-guided radiotherapy for gynecologic cancer: An R-IDEAL stage 1/2a first in humans/feasibility study of new technology implementation}},
  year = {2021},
  doi = {10.1101/2021.12.03.21266962},
  howpublished = {medRxiv},
}
Figure